

Seasonal Vaccine Information (COVID-19, Flu, RSV)

Respiratory Syncytial Virus (RSV) Vaccine Programs:

The RSV season is generally from November 1 to March 31.

Older Adult (Arexvy®, Abrysvo®)

- Eligibility for publicly funded RSV vaccine has expanded to include **all individuals aged 75 and older**.
- Eligibility continues to include individuals 60 to 74 years of age who are at high risk. See [Older Adult High-Risk Respiratory Syncytial Virus \(RSV\) Vaccine Program Fact Sheet - Health Care Providers](#) for high-risk criteria.
- Booster doses are not recommended. If an individual has previously received a dose of RSV vaccine, they do not need to receive another dose this season.

Infant and High-Risk Child (Beyfortus®)

- Infants born April 1, 2025, or after **AND** are less than 8 months of age until the end of the RSV season are eligible for Beyfortus®.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season are eligible for Beyfortus®. See [Infant and High-risk Children Respiratory Syncytial Virus \(RSV\) Prevention Program Factsheet for Health Care Providers](#) for high-risk criteria and dosing.
- For infants born in hospital, Beyfortus® should be administered prior to discharge.
- RSV vaccine administration can begin in early October.

The National Advisory Committee on Immunization (NACI) preferentially recommends the use of Beyfortus® for infant protection due to its effectiveness, long-lasting protection, and positive safety profile.

Pregnancy (Abrysvo®)

- A pregnant person between 32-36 weeks' gestation who will deliver during the RSV season, may elect to have a dose of Abrysvo® instead of providing Beyfortus® to their infant following a discussion with a health care provider. See [Infant and High-risk Children Respiratory Syncytial Virus \(RSV\) Prevention Program Factsheet for Health Care Providers](#) for more information.

NOTE: Administration of both the Abrysvo® vaccine to the pregnant individual and Beyfortus® to the infant is NOT recommended except under specific circumstances as noted in the fact sheet.

COVID-19 Vaccine Program:

- The two brands of COVID-19 vaccines available for 2025-2026 are Moderna Spikevax LP.8.1 and Pfizer Comirnaty LP.8.1. Novavax will NOT be available in Ontario.
- High risk individuals and priority populations aged 6 months and older should receive a dose of COVID-19 vaccine as soon as it becomes available. See [Health Care Provider Fact Sheet: 2025/26 COVID-19 Vaccine Program](#) for high-risk criteria.
- Vaccination of the general population begins October 27, 2025.

Influenza Vaccine Program:

- Trivalent influenza vaccines are available. Quadrivalent vaccines are no longer being used as one of the B/strains is no longer circulating.
- Available vaccines include:
 - Trivalent inactivated vaccine (TIV) for 6 months of age and older
 - High-dose trivalent inactivated vaccine (TIV-HD) for 65 years of age and older
 - Adjuvanted trivalent inactivated vaccine (TIV-adj) for 65 years of age and older
- Immunization of high risk and priority populations should begin as soon as the flu vaccine is available. See [Universal Influenza Immunization Program | ontario.ca](#) for high-risk criteria.
- Vaccination of the general population begins October 27, 2025.

NOTE: All of the above vaccines can be co-administered.

If you have any questions, please contact your local public health office:

Phone number: 1-844-575-4567

Email:

Haliburton, City of Kawartha Lakes, and Northumberland: immunization@hkpr.on.ca

Peterborough: schoolvaccines@peterboroughpublichealth.ca